Cannabis therapy for HIV patients shows promise for appetite stimulation and neuropathic pain management, but requires careful consideration of drug interactions with antiretroviral therapy. Clinical evidence supports modest but meaningful improvements in HIV-associated symptoms when properly integrated with comprehensive care. Patients should work closely with HIV specialists familiar with cannabis medicine to ensure safe and effective treatment protocols.
Cannabinoids for Nerve Pain: What the Best Clinical Evidence Says About Sleep and Pain Relief
This review of cannabinoids for neuropathic pain sleep examines a 2022 meta-analysis of eight randomized controlled trials involving 1,051 patients with chronic neuropathic pain. The findings showed statistically significant improvements in both sleep quality and pain intensity, alongside clinically important patient-reported improvements. The study also highlights important limitations, formulation variability, and safety considerations clinicians should discuss with patients considering cannabinoid therapy.
Cannabis Medicines Show Modest Promise for Nerve Pain, But Evidence Remains Inconclusive
CBM treatments may improve pain scores, but study limitations such as small sample sizes and study durations, high placebo response rates, and trial unblinding because of the psychoactive effects of cannabinoids all hinder data interpretation and the extrapolation to chronic pain conditions.
Cannabis Medicines Show Modest Promise for Nerve Pain, But Evidence Remains Inconclusive
CBM treatments may improve pain scores, but study limitations such as small sample sizes and study durations, high placebo response rates, and trial unblinding because of the psychoactive effects of cannabinoids all hinder data interpretation and the extrapolation to chronic pain conditions.
Cannabis for Nerve Pain: Mixed Evidence From 22 Trials, No Clear Winners Yet
Collectively, CBM treatments may improve pain scores, but study limitations such as small sample sizes and study durations, high placebo response rates, and trial unblinding because of the psychoactive effects of cannabinoids all hinder data interpretation and the extrapolation to chronic pain conditions.
Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
Neurocutaneous dysesthesia (ND) is characterized by abnormal skin sensations such as pruritus or burning without an underlying skin condition. It is caused b…
Neuropathic Pain Severity Is Associated With Opioid Use in Adults With Traumatic Spinal Cord Injury: A Spinal Cord Injury Model System Study.
A new study of 283 spinal cord injury patients reveals that neuropathic pain severity predicts opioid use, while employment status reduces opioid dependence risk by 33%. The research highlights complex medication patterns including cannabis combinations among this vulnerable population requiring specialized pain management approaches.
Assessments of Evoked and Spontaneous Pain Following Administration of Gabapentin and the Cannabinoid CB
A preclinical study demonstrates that CB2 receptor agonist neuropathic pain treatment may address both mechanical hypersensitivity and spontaneous pain components. While promising mechanistically, this research requires human validation before clinical application.
Cannabis-based medicines for chronic neuropathic pain in adults.
The 2025 Cochrane review on cannabis neuropathic pain provides the most rigorous analysis of cannabinoid effectiveness for chronic nerve pain. This systematic review update incorporates recent trial data to inform evidence-based clinical decision-making for neuropathic pain treatment options.
Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review.
New systematic review evidence shows cannabis for diabetic peripheral neuropathy can provide significant pain relief, with THC-containing products demonstrating the strongest efficacy. This research offers clinicians evidence-based guidance for considering cannabinoid interventions in treatment-resistant diabetic nerve pain cases.